Literature DB >> 21893021

mdx(⁵cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice.

Nicholas Beastrom1, Haiyan Lu, Allison Macke, Benjamin D Canan, Eric K Johnson, Christopher M Penton, Brian K Kaspar, Louise R Rodino-Klapac, Lan Zhou, Paul M L Janssen, Federica Montanaro.   

Abstract

Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal muscle dysfunction leading to premature death by the third decade of life. The mdx mouse, the most widely used animal model of DMD, has been extremely useful to study disease mechanisms and to screen new therapeutics. However, unlike patients with DMD, mdx mice have a very mild motor function deficit, posing significant limitations for its use as a platform to assess the impact of treatments on motor function. It has been suggested that an mdx variant, the mdx(5cv) mouse, might be more severely affected. Here, we compared the motor activity, histopathology, and individual muscle force measurements of mdx and mdx(⁵cv) mice. Our study revealed that mdx(⁵cv) mice showed more severe exercise-induced fatigue, Rotarod performance deficits, and gait anomalies than mdx mice and that these deficits began at a younger age. Muscle force studies showed more severe strength deficits in the diaphragm of mdx(⁵cv) mice compared to mdx mice, but similar force generation in the extensor digitorum longus. Muscle histology was similar between the two strains. Differences in genetic background (genetic modifiers) probably account for these functional differences between mdx strains. Overall, our findings indicate that the mdx and mdx(⁵cv) mouse models of DMD are not interchangeable and identify the mdx(⁵cv) mouse as a valuable platform for preclinical studies that require assessment of muscle function in live animals.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893021      PMCID: PMC3204025          DOI: 10.1016/j.ajpath.2011.07.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.

Authors:  Mary Rucker; Thomas J Fraites; Stacy L Porvasnik; Melissa A Lewis; Irene Zolotukhin; Denise A Cloutier; Barry J Byrne
Journal:  Development       Date:  2004-06       Impact factor: 6.868

2.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 3.  Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.

Authors:  Chalermchai Mitrpant; Sue Fletcher; Steve D Wilton
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

4.  Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle.

Authors:  R J Zeman; H Peng; M J Danon; J D Etlinger
Journal:  Muscle Nerve       Date:  2000-04       Impact factor: 3.217

5.  Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice.

Authors:  J A Rafael; Y Nitta; J Peters; K E Davies
Journal:  Mamm Genome       Date:  2000-09       Impact factor: 2.957

6.  Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.

Authors:  Scott Q Harper; Michael A Hauser; Christiana DelloRusso; Dongsheng Duan; Robert W Crawford; Stephanie F Phelps; Hollie A Harper; Ann S Robinson; John F Engelhardt; Susan V Brooks; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

7.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

8.  Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice.

Authors:  Ahlke Heydemann; Ermelinda Ceco; Jackie E Lim; Michele Hadhazy; Pearl Ryder; Jennifer L Moran; David R Beier; Abraham A Palmer; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice.

Authors:  Christine I Wooddell; Guofeng Zhang; Jacob B Griffin; Julia O Hegge; Thierry Huss; Jon A Wolff
Journal:  Muscle Nerve       Date:  2010-04       Impact factor: 3.217

10.  Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery.

Authors:  Louise R Rodino-Klapac; Chrystal L Montgomery; William G Bremer; Kimberly M Shontz; Vinod Malik; Nancy Davis; Spencer Sprinkle; Katherine J Campbell; Zarife Sahenk; K Reed Clark; Christopher M Walker; Jerry R Mendell; Louis G Chicoine
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more
  33 in total

1.  Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophy.

Authors:  Danielle A Griffin; Ryan W Johnson; Jarred M Whitlock; Eric R Pozsgai; Kristin N Heller; William E Grose; W David Arnold; Zarife Sahenk; H Criss Hartzell; Louise R Rodino-Klapac
Journal:  Hum Mol Genet       Date:  2016-02-23       Impact factor: 6.150

Review 2.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

3.  Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy.

Authors:  Kenneth M Estrellas; Liam Chung; Lindsay A Cheu; Kaitlyn Sadtler; Shoumyo Majumdar; Jyothi Mula; Matthew T Wolf; Jennifer H Elisseeff; Kathryn R Wagner
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

Review 4.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

5.  Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice.

Authors:  Congshan Sun; In Young Choi; Yazmin I Rovira Gonzalez; Peter Andersen; C Conover Talbot; Shama R Iyer; Richard M Lovering; Kathryn R Wagner; Gabsang Lee
Journal:  JCI Insight       Date:  2020-06-04

6.  Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.

Authors:  Eric R Pozsgai; Danielle A Griffin; Kristin N Heller; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

7.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.

Authors:  Matthew S Alexander; Juan Carlos Casar; Norio Motohashi; Natássia M Vieira; Iris Eisenberg; Jamie L Marshall; Molly J Gasperini; Angela Lek; Jennifer A Myers; Elicia A Estrella; Peter B Kang; Frederic Shapiro; Fedik Rahimov; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

8.  In vivo assessment of contractile strength distinguishes differential gene function in skeletal muscle of zebrafish larvae.

Authors:  Brit L Martin; Thomas L Gallagher; Neha Rastogi; Jonathan P Davis; Christine E Beattie; Sharon L Amacher; Paul M L Janssen
Journal:  J Appl Physiol (1985)       Date:  2015-08-06

9.  Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling.

Authors:  Genri Kawahara; Molly J Gasperini; Jennifer A Myers; Jeffrey J Widrick; Alal Eran; Peter R Serafini; Matthew S Alexander; Mathew T Pletcher; Carl A Morris; Louis M Kunkel
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

10.  CCR2 deficiency does not provide sustained improvement of muscular dystrophy in mdx5cv mice.

Authors:  Wanming Zhao; Xingyu Wang; Richard M Ransohoff; Lan Zhou
Journal:  FASEB J       Date:  2016-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.